At a Glance*

Launched in: 2006
Currently working with: 26 countries

USAID Investment
3.1 billion treatments delivered
1.6 billion people treated
$29.9 billion leveraged in donated drugs
8.1 million individuals trained strengthening the expertise and capacity of country partners

Health Impact
13 USAID-supported countries have eliminated at least one NTD as a public health problem
People no longer requiring treatment for lymphatic filariasis: 391 million
People no longer requiring treatment for trachoma: 196 million
People no longer requiring treatment for onchocerciasis: 14.7 million

The Future
15 countries will eliminate at least one NTD as a public health problem within 5 years
12 USAID-supported countries have or are developing NTD sustainability plans

Updated: September 2023

Neglected Tropical Diseases

Neglected tropical diseases (NTDs) cause illness and lifelong disabilities for more than a billion people worldwide. Not addressing NTDs traps individuals and communities in poverty, undermines growth and development, and impairs progress towards achieving global health and development goals. Since 2006, the Agency has supported more than 30 countries to combat five of the most common NTDs.

USAID targets five of the most common NTDs that have proven, cost-effective health interventions:

- Lymphatic Filariasis (elephantiasis)
- Blinding Trachoma
- Onchocerciasis (river blindness)
- Schistosomiasis (snail fever)
- Soil Transmitted Helminths (intestinal worms - hookworm, roundworm, whipworm)

Our Objectives

The United States Agency for International Development (USAID) works alongside endemic countries and with global, regional, and in-country partners to improve health and end NTDs. USAID’s NTD Program has four key objectives.

Key objectives and approaches to accelerate progress on ending NTDs:

- **Controlling & eliminating diseases**
  - **Mapping** to find communities at-risk of these NTDs
  - **Treating** at-risk communities with safe, effective, donated medicines — treating for more than one disease at a time where appropriate
  - **Measuring** progress and documenting impact of the control and elimination of NTDs
- **Supporting sustainable country-led programs**
  - **Supporting** government-developed, multi-sectoral sustainability plans for NTD prevention and treatment
  - **Reinforcing** national governance of NTD programs
  - **Strengthening** health systems to deliver NTD services
- **Strengthening the scientific & program evidence base**
  - **Investing in operational research** to generate and advance evidence that can then be used to remove barriers to progress, improve program efficiencies, and protect public health gains
  - **Supporting diagnostic innovations** to improve delivery of NTD services, use of program resources, and measuring progress towards control and elimination targets
- **Partnering** with host governments, pharmaceutical companies, private and government donors, non-governmental organizations, and researchers

*Cumulative results from 2006 to 2022
Results Over the Years

<table>
<thead>
<tr>
<th>Program Stage</th>
<th>Fiscal Years</th>
<th>Number of Countries Supported</th>
<th>Number of Districts Mapped</th>
<th>Number of Treatments Delivered</th>
<th>U.S. Government Investment</th>
<th>Value of Drug Donations in USAID-supported countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proof of Principle</td>
<td>2006 - 2010</td>
<td>12</td>
<td>181</td>
<td>386 million</td>
<td>$135 million</td>
<td>$2,174 billion</td>
</tr>
<tr>
<td>Global Expansion</td>
<td>2011 - 2015</td>
<td>25</td>
<td>2,389</td>
<td>1.2 billion</td>
<td>$451 million</td>
<td>$8,965 billion</td>
</tr>
<tr>
<td>Acceleration</td>
<td>2016 - 2020</td>
<td>27</td>
<td>292</td>
<td>1.1 billion</td>
<td>$505 million</td>
<td>$14,963 billion</td>
</tr>
<tr>
<td>Achieving Elimination</td>
<td>2021 -</td>
<td>26</td>
<td>72</td>
<td>305.7 million</td>
<td>$210 million</td>
<td>$2,299 billion</td>
</tr>
</tbody>
</table>

Private Sector Donations

Our success is underpinned by a dynamic public-private partnership with the pharmaceutical industry, which enables USAID to carry out the largest integrated NTD program in the world, ensuring that treatments reach those in need. Leading pharmaceutical companies have made unprecedented donations to tackle the most common NTDs by providing drugs free of charge.

- Eisai Co., Ltd.
- Johnson & Johnson
- Merck KGaA
- Pfizer
- GSK
- Merck & Co. Inc.

Where We Work

USAID-supported countries that have eliminated at least one disease, per the WHO:

USAID-supported country governments that have completed an NTD sustainability plan:
- Ivory Coast (2020), Senegal, Uganda, Togo, & Ghana (2021), Tanzania, Ethiopia, & Niger (2022), Mali (2023)

Country Successes

USAID-supported countries that have eliminated at least one NTD:
- Onchocerciasis: Colombia, Ecuador, Mexico, Guatemala
- Trachoma: Cambodia, Laos, Nepal, Ghana
- Lymphatic Filariasis: Cambodia, Vietnam

USAID-supported country governments that have developed a sustainability plan:
- Ivory Coast, Senegal, Uganda, Togo, Ghana, Tanzania, Ethiopia, Niger

To date: Every $1 invested by the U.S. Government leverages $26 in donated medicines for mass treatment campaigns totalling $29.9 billion in value.

USAID FACT SHEET WORKING TO PROTECT AGAINST NEGLECTED TROPICAL DISEASES

The United States Agency for International Development (USAID) leads international development and humanitarian efforts to save lives, reduce poverty, strengthen democratic governance, and help people progress beyond assistance.